Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Total Current Liabilities (2023 - 2025)

Kura Oncology (KURA) has disclosed Total Current Liabilities for 3 consecutive years, with $117.0 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 48.61% to $117.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $117.0 million through Dec 2025, up 48.61% year-over-year, with the annual reading at $117.0 million for FY2025, 48.61% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $117.0 million at Kura Oncology, down from $121.3 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $121.3 million in Q3 2025, with the low at $19.2 million in Q1 2023.
  • Average Total Current Liabilities over 3 years is $60.5 million, with a median of $37.8 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities surged 39.97% in 2024, then surged 220.39% in 2025.
  • Over 3 years, Total Current Liabilities stood at $35.3 million in 2023, then soared by 123.21% to $78.7 million in 2024, then soared by 48.61% to $117.0 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $117.0 million, $121.3 million, and $107.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.